Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY26 results · Apr–Jun 2025
Bliss GVS Pharma reported revenue from operations of ₹207.47 crore (up 13.0% from Q1 FY25) and net profit of ₹44.36 crore (up 100.7% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 207.47 | 183.64 | +13.0% | 197.99 | +4.8% |
| Other income | 35.45 | 4.12 | +760.0% | 12.07 | +193.8% |
| Total income | 242.92 | 187.77 | +29.4% | 210.05 | +15.6% |
| Profit before tax | 63.11 | 30.07 | +109.9% | 23.44 | +169.2% |
| Net profit for the period | 44.36 | 22.11 | +100.7% | 16.65 | +166.4% |
| Attributable to shareholders of the company | 43.04 | 20.70 | +107.9% | 15.54 | +177.0% |
| EPS, basic (₹) | 4.08 | 1.97 | +107.1% | 1.47 | +177.6% |
| Net margin (%) | 21.4 | 12.0 | 8.4 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 163.36 | 148.96 | +9.7% | 156.00 | +4.7% |
| Other income | 10.59 | 6.84 | +54.8% | 9.36 | +13.2% |
| Total income | 173.96 | 155.80 | +11.7% | 165.36 | +5.2% |
| Profit before tax | 30.56 | 26.15 | +16.9% | 14.36 | +112.9% |
| Net profit for the period | 21.05 | 19.42 | +8.4% | 11.45 | +83.8% |
| EPS, basic (₹) | 2.00 | 1.85 | +8.1% | 1.08 | +85.2% |
| Net margin (%) | 12.9 | 13.0 | 7.3 |
Consolidated
- Filed with BSE
- 29 Jul 2025, 18:49 IST
- Board meeting
- 29 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2025, 18:49 IST
- Board meeting
- 29 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE